SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

BACKGROUND: Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised co...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarthy, Caroline, Sacco, Joseph, Fedele, Stefano, Ho, Michael, Porter, Stephen, Liloglou, Triantafillos, Greenhalf, Bill, Robinson, Max, Young, Bridget, Cicconi, Silvia, Chauhan, Seema, Tesfaye, Binyam, Jackson, Richard, Sherratt, Frances, Shaw, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256209/
https://www.ncbi.nlm.nih.gov/pubmed/34225765
http://dx.doi.org/10.1186/s13063-021-05373-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256209/
https://www.ncbi.nlm.nih.gov/pubmed/34225765
http://dx.doi.org/10.1186/s13063-021-05373-8

Ejemplares similares